They evaluated 3 years of treatment with slow-release niacin plus simvastatin (N+S) on both angiographic and clinical outcomes in 160 subjects with coronary artery disease (CAD) and low levels of ...

Low HDL-cholesterol concentrations can be successfully raised by niacin. A low HDL-cholesterol level is recognized as a coronary risk factor and increases the risk of unfavorable events related to ...

Extended-release form of the vitamin can reduce the adverse effects, but currently it is not available in Europe. Niacin is quite stable as a compound. Niacin products often include both nicotinamide ...